The Bright Hour: Metastatic Breast Cancer at 37, and What Screening Was Never Going to Do

The Bright Hour: A Memoir of Living and Dying is Nina Riggs's account of the last two years of her life. Scribner published it in June 2017.

Her publisher's page states the facts plainly: Riggs was a poet and the mother of two young sons, she was diagnosed with breast cancer at age 37, and within a year she learned that her cancer was terminal.

Spoilers throughout. Riggs died in February 2017, before publication. Her husband, John Duberstein, wrote the afterword. The book was always going to end this way and does not pretend otherwise, so this page does not treat her death as a reveal.

It is not a book about breast cancer as a disease. It is a book about running a household, raising children, being married and being a daughter while a diagnosis moves from small to serious to final. Her mother is also dying of cancer during part of it.

The structure is the most distinctive thing about it. There are no long chapters. Instead there are dozens of very short sections, some a page, some three, each with its own title.

Broadly it moves in time. The first stretch is diagnosis and early treatment, framed by what she was told was one small spot. Then progression: a new pain, a scan, the reframing of everything. Then her mother's decline and death running alongside her own. Then the last months, treatment decisions narrowing, and the practical work of preparing a family.

Two literary presences run through it. Ralph Waldo Emerson, who was her great-great-great-grandfather, and Michel de Montaigne, whose essays she reads and quotes. Her publisher names both. They function less as scholarship than as company. Montaigne in particular gives her a model for the form itself: short pieces, written to think rather than to conclude, willing to change their mind between one and the next.

There is no appendix, no glossary, no resource list, no medical explanation section. The clinical material appears only where it appears in her life: a waiting room, a phone call, a scan result delivered badly. Readers who want the disease explained will have to go elsewhere, and the book is untroubled by that.

It is strongest on the domestic scale of illness.

Most cancer memoirs organise themselves around the disease. This one organises itself around a house with two boys in it, and lets the disease interrupt. A section about a sofa purchase is really about whether she will be alive to sit on it. She never says that. She does not have to.

The effect is cumulative rather than dramatic. No single section carries much weight. Fifty of them, read in order, add up to a fairly exact picture of what two years of this does to a family's ordinary business, which is something longer and more argued books often miss.

It is also genuinely funny, which readers rarely expect. The comedy is not brave-face comedy. It is the specific humour of someone who has been in enough scanners to find the ritual absurd.

And it is precise about the double burden of being a dying daughter of a dying mother. The two illnesses are not treated as parallel or poetic. They are two sets of appointments in the same family calendar.

Finally, it is good on marriage under this pressure, including a late passage where she thinks about her husband's life after her, which is unusual for a book written from inside the illness.

The treatment details are from roughly 2015 to 2017. Drug options, sequencing and expectations in metastatic breast cancer have changed since, and nothing in the book should be read as current practice or as a comparison against anyone's current plan.

The book gives no systematic account of her pathology. Readers looking to map her case onto their own will not find the receptor status, the exact regimens or the trial context laid out. That is a legitimate authorial choice, but it means the book cannot answer the question many readers bring to it.

Her circumstances are also not universal. She has a supportive spouse, an intact household, a literary vocabulary and access to care. Money, insurance, transport and time off work barely appear.

And the short-section form, which some readers find perfectly judged, others find fragmentary. If you want narrative build, this is not that.

One more caution, less about the book than about how it gets recommended. It is often handed to newly diagnosed people as reassurance. It is not reassurance. Riggs's disease progresses and she dies, and a reader in the early-stage setting who reads it as a forecast will draw a conclusion the book does not support. Most breast cancer diagnosed in the United States is not metastatic at diagnosis, and a memoir is not a prognosis.

This is the concrete thing the book raises without arguing about it.

USPSTF recommends biennial screening mammography for women aged 40 to 74 years. That is a Grade B recommendation, updated in 2024, and it applies to all women from 40 rather than leaving the forties to individual choice as earlier versions did.

Below 40, USPSTF gives no recommendation. The reason is stated in the guideline: the trials that inform it did not enroll women younger than 39, so there is insufficient evidence to weigh benefits against harms. Above 74, USPSTF also says the evidence is insufficient, a Grade I statement. For women with dense breasts, USPSTF likewise says the evidence on supplemental ultrasound or MRI is insufficient, another Grade I statement.

So for a 37-year-old at average risk, routine mammography is not on offer, and the guideline is explicit that this is about missing evidence rather than proven absence of benefit. Women at high risk are handled under different guidance. That includes some with BRCA variants or a strong family history. A population screening recommendation does not cover them. That distinction matters when reading a book like this one. A story about a young woman with advanced disease naturally raises the question of whether screening should start earlier for everyone. The guideline's answer is narrower than people expect: for women under 40, the evidence to settle that question does not yet exist.

That leaves symptoms. NCI's list of possible cancer signs includes breast changes such as a lump, nipple discharge or skin changes, unexplained swelling or lumps anywhere, unexplained weight changes, and severe lasting fatigue. NCI's instruction is the one worth remembering: if symptoms do not get better after a few weeks, see a doctor so problems can be diagnosed and treated as early as possible.

For the full picture of ages, intervals and what a mammogram does and does not do, see breast cancer screening.

Two things get flattened in conversations about this book, and federal sources are clear on both.

The first is survival statistics. NCI reports 5-year relative survival for female breast cancer at 91.2 percent, with an estimated 310,720 new cases and 42,250 deaths in a year, and about 13.1 percent of women receiving a breast cancer diagnosis in their lifetime. That 91 percent is an average across all stages at diagnosis. It does not describe metastatic disease, and NCI states directly that such statistics are based on large groups of people and cannot predict what will happen to an individual.

The second is what metastatic treatment is for. For stage IV, NCI describes treatment aimed at managing the disease and protecting quality of life. The tools are chemotherapy, targeted therapies, immunotherapy, and surgery or radiation to relieve symptoms. That is a different goal from cure, and it is stated as such rather than implied. It also does not mean treatment stops or that time is short by definition; it means the measure of success is different, and the conversation about goals happens earlier and more often.

Triple-negative breast cancer is worth understanding here even though the book does not name Riggs's receptor status. NCI describes it as breast cancer that does not have the targets typically used to treat other types of breast cancer. For stages I to III, NCI lists several options. Surgery. Chemotherapy, sometimes given before surgery to shrink a larger tumor. The immunotherapy drug pembrolizumab, alongside chemotherapy. Olaparib, for people with BRCA variants. And radiation. For stage IV, it lists chemotherapy, olaparib, sacituzumab govitecan, immunotherapy, and surgery or radiation for symptoms.

See triple-negative breast cancer explained and metastatic breast cancer: what now for how those results and goals are discussed in an appointment. Riggs was 37. No screening programme would have included her, which is the quiet fact underneath the whole memoir.

It suits readers living in a household with cancer in it, particularly parents of young children, and readers who would rather have company than instruction. It suits people who find humour steadying and grand statements suffocating.

It does not suit a reader who needs to understand their own diagnosis, because the book deliberately declines to explain. It may also be too close for someone recently given a metastatic breast cancer diagnosis at a young age. That is not squeamishness, and there is no obligation to read it.

For what the care she received in the last months is called and what it does, see palliative care.

• The Bright Hour — publisher's page (Scribner)
• USPSTF — Breast Cancer: Screening
• NCI SEER — Cancer Stat Facts: Female Breast Cancer
• NCI — Triple-Negative Breast Cancer Treatment
• NCI — Breast Cancer Treatment (PDQ) Patient Version
• NCI — Symptoms of Cancer

This page discusses The Bright Hour for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care.